Latest & greatest articles for covid-19

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on covid-19 or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on covid-19 and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for covid-19

181. Updated COVID-19 advice for pregnant employees

Updated COVID-19 advice for pregnant employees Coronavirus (COVID-19): advice for pregnant employees - GOV.UK Cookies on GOV.UK We use some essential cookies to make this website work. We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services. We also use cookies set by other sites to help us deliver content from their services. Accept additional cookies Reject additional cookies You can at any time. Hide this message Show (...) or hide search Search on GOV.UK Search National lockdown: stay at home Check what you need to do Guidance Coronavirus (COVID-19): advice for pregnant employees Updated 11 January 2021 © Crown copyright 2021 This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: . Where we have identified any third party copyright information

2021 ICM Anaesthesia COVID-19

182. Testing Strategies for COVID-19

Testing Strategies for COVID-19 Implementation of objective-driven and sustainable testing strategies for COVID-19 supports the overall public health response to the pandemic and helps mitigate its impact on vulnerable populations and healthcare systems, while ensuring that societies and economies can continue to function. Testing strategies should be flexible and rapidly adaptable to change, depending on the local epidemiology, transmission, population dynamics and resources. This rapid review (...) provides evidence on testing strategy for COVID-19 in a few epidemiological situations, including general population-wide testing, as well as targeted testing of individuals following a request from the crisis preparedness response centre for possibility of strategy enhancement. There were several articles and guidelines retrieved from the scientific databases such as Medline, EBM Reviews, EMBASE via OVID, PubMed and from the general search engines [Google Scholar and US Food and Drug Administration

2021 MaHTAS Covid-19 Rapid Evidence Updates

183. COVID-19 Vaccine Moderna

COVID-19 Vaccine Moderna Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. EMA/704373/2020 EMEA/H/C/005735 COVID-19 Vaccine Moderna (COVID-19 mRNA vaccine [nucleoside modified (...) ]) An overview of COVID-19 Vaccine Moderna and why it is authorised in the EU What is COVID-19 Vaccine Moderna and what is it used for? COVID-19 Vaccine Moderna is a vaccine for preventing coronavirus disease 2019 (COVID-19) in people aged 18 years and older. COVID-19 Vaccine Moderna contains a molecule called messenger RNA (mRNA) with instructions for producing a protein from SARS-CoV-2, the virus that causes COVID-19. COVID-19 Vaccine Moderna does not contain the virus itself and cannot cause COVID-19. How

2021 European Medicines Agency - EPARs

184. Public health guidance for community and healthcare settings in the context of COVID-19

Public health guidance for community and healthcare settings in the context of COVID-19 Rapid review of current public health guidance for community settings and infection prevention and control measures in healthcare settings for COVID-19 Health Information and Quality Authority Page 1 of 79 Current public health guidance for community settings and infection prevention and control measures in healthcare settings for COVID-19: a rapid review Submitted to NPHET: 13 January 2021 Published 29 (...) January 2021 Rapid review of current public health guidance for community settings and infection prevention and control measures in healthcare settings for COVID-19 Health Information and Quality Authority Page 2 of 79 About the Health Information and Quality Authority The Health Information and Quality Authority (HIQA) is an independent statutory authority established to promote safety and quality in the provision of health and social care services for the benefit of the health and welfare

2021 Health Information and Quality Authority

185. Development and validation of a risk score using complete blood count to predict in-hospital mortality in COVID-19 patients Full Text available with Trip Pro

Development and validation of a risk score using complete blood count to predict in-hospital mortality in COVID-19 patients Development and validation of a risk score using complete blood count to predict in-hospital mortality in COVID-19 patients - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly (...) Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Med (N Y) Actions . 2021 Jan 8. doi: 10.1016/j.medj.2020.12.013. Online ahead of print. Development and validation of a risk score using complete blood count to predict in-hospital mortality in COVID-19 patients

2021 EvidenceUpdates

186. Protective measures for groups vulnerable to COVID-19

Protective measures for groups vulnerable to COVID-19 Rapid review of public health guidance on protective measures for vulnerable groups Health Information and Quality Authority Page 1 of 82 Rapid review of public health guidance on protective measures for vulnerable groups in the context of COVID-19 Updated on: 4 February 2021 Rapid review of public health guidance on protective measures for vulnerable groups Health Information and Quality Authority Page 2 of 82 Version history Version Date (...) review of public health guidance on protective measures for vulnerable groups Health Information and Quality Authority Page 9 of 82 Key points ? A variety of protective measures are being taken to protect vulnerable groups who are at high risk of severe illness from COVID-19 in all countries included in this review. ? In general, people who are considered vulnerable to more severe illness are those that are of an older age, with chronic conditions if not well-managed or are in receipt of therapies

2021 Health Information and Quality Authority

187. Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study Full Text available with Trip Pro

Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study CDEI - Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study — CDEI Open Menu Close Menu Open Menu Close Menu Feb 13 Written By Citation: Dabbous, H. M. , Abd-Elsalam, S., El-Sayed, M. H., Sherief, A. F., Ebeid, F. F., Abd El Ghafar, M. S., ... & Tageldin, M. A. (2021). Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study. Archives of Virology , 1-6. DOI: Journal (...) response was not investigated. Study included only COVID-19 patients who were mildly or moderately ill and therefore had a better prognosis that severely or critically ill patients Results Low external validity as the study only included patients with mild-moderate COVID-19 infection. Furthermore, participants in the study were relatively young (mean age of 35 years old) and thus jeopardizing the generalizability to older patients. Abbreviations ALT = alanine aminotransferase AST = aspartate

2021 Covid-19 Drug Evidence Initiative

188. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19 Full Text available with Trip Pro

Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19 CDEI - Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19 — CDEI Open Menu Close Menu Open Menu Close Menu Feb 11 Written By Citation: Gottlieb, L. R. , Nirula, A., Chen, P., Boscia, J., Heller, B., Morris, J., … Huhn, G. (2021). Effect of bamlanivimab as monotherapy or in combination (...) with etesevimab on viral load in patients with mild to moderate COVID-19. JAMA . DOI: Journal impact factor: 45.540 (JAMA) Full PICO and Limitations in text: Population: 577 adult (≥18 years) patients diagnosed with direct antigen or PCR-confirmed mild or moderate SARS-CoV-2 infection in outpatient setting, who presented within 3 days of their first positive test result. Intervention and Comparator Intervention 1: 101 patients. Bamalanivimab (700 mg IV x 1 infusion). Intervention 2: 107 patients

2021 Covid-19 Drug Evidence Initiative

189. Rapid Review: What is known about the risk of transmission of COVID-19 during musical activities such as singing or playing a wind instrument, and how can these risks be mitigated?

Rapid Review: What is known about the risk of transmission of COVID-19 during musical activities such as singing or playing a wind instrument, and how can these risks be mitigated? Rapid Review: What is known about the risk of transmission of COVID-19 during musical activities such as singing or playing a wind instrument, and how can these risks be mitigated? | Covid-19 Rapid Review | National Collaborating Centre for Methods and Tools This browser does not support PDFs, or the PDF is too large

2021 COVID-19 Rapid Evidence Service

190. Using face masks in the community: first update - Effectiveness in reducing transmission of COVID-19

Using face masks in the community: first update - Effectiveness in reducing transmission of COVID-19 Suggested citation: European Centre for Disease Prevention and Control. Using face masks in the community: first update. 15 February 2021. ECDC: Stockholm; 2021. © European Centre for Disease Prevention and Control, Stockholm, 2021. ; TECHNICAL REPORT Using face masks in the community: first update Effectiveness in reducing transmission of COVID-19 15 February 2021 Key messages The role of face (...) masks in the control and prevention of COVID-19 remains an issue of debate. Prior to COVID-19, most studies assessing the effectiveness of face masks as a protective measure in the community came from studies on influenza, which provided little evidence to support their use. This technical report reviews the evidence that has been accumulated since the emergence of COVID-19, in addition to what has existed on this topic prior to the pandemic, and updates the ECDC opinion on the suitability of using

2021 European Centre for Disease Prevention and Control - Covid-19 Guidance

191. Interventions in an ambulatory setting to prevent progression to severe disease in patients with COVID-19

Interventions in an ambulatory setting to prevent progression to severe disease in patients with COVID-19 Advice to the National Public Health Emergency Team: Interventions in an ambulatory setting to prevent progression to severe disease in patients with COVID-19 Health Information and Quality Authority Page 1 of 16 Advice to the National Public Health Emergency Team: Interventions in an ambulatory setting to prevent progression to severe disease in patients with COVID-19 Published: 5 February (...) 2021 Submitted to NPHET: 27 January 2021 Advice to the National Public Health Emergency Team: Interventions in an ambulatory setting to prevent progression to severe disease in patients with COVID-19 Health Information and Quality Authority Page 2 of 16 About the Health Information and Quality Authority The Health Information and Quality Authority (HIQA) is an independent statutory authority established to promote safety and quality in the provision of health and social care services

2021 Health Information and Quality Authority

192. Residential care facilities; COVID-19 public health guidance

Residential care facilities; COVID-19 public health guidance Rapid review of public health guidance for residential care facilities Health Information and Quality Authority Page 1 of 76 Rapid review of public health guidance for residential care facilities in the context of COVID-19 5 Febuary 2021 Rapid review of public health guidance for residential care facilities Health Information and Quality Authority Page 2 of 76 Version history Version Date Specific updates V1.0 30 March 2020 Date (...) of first rapid review V1.1 31 March 2020 Addition of guidance from Germany, the Communicable Disease Network Australia and Hong Kong Update of conclusion Addition of Table 2 Addition of section on restrictive measures pertaining to residential care facilities V1.2 16 April 2020 Updated to include differences in guidance since the initial review. Review expanded to include information on guidance for residential care facilities with no known cases of COVID-19. V1.3 22 April 2020 Updated to include

2021 Health Information and Quality Authority

193. COVID-19: management of staff and exposed patients and residents in health and social care settings

COVID-19: management of staff and exposed patients and residents in health and social care settings COVID-19: management of exposed healthcare workers and patients in hospital settings - GOV.UK Tell us whether you accept cookies We use about how you use GOV.UK. We use this information to make the website work as well as possible and improve government services. Accept all cookies You’ve accepted all cookies. You can at any time. Hide Search Stay at home Only go outside for food, health reasons (...) or work (but only if you cannot work from home) If you go out, stay 2 metres (6ft) away from other people at all times Wash your hands as soon as you get home Do not meet others, even friends or family. You can spread the virus even if you don’t have symptoms. Guidance COVID-19: management of exposed healthcare workers and patients in hospital settings Guidance on the management of hospital staff and patients who have been exposed to COVID-19. Published 4 April 2020 From: Documents HTML Details

2021 Public Health England

194. Open versus Closed: The Risks Associated with Retail Liquor Stores during COVID-19

Open versus Closed: The Risks Associated with Retail Liquor Stores during COVID-19 www.ccsa.ca • www.ccdus.ca Canadian Centre on Substance Use and Addiction • Centre canadien sur les dépendances et l’usage de substances Page 1 Open versus Closed: The Risks Associated with Retail Liquor Stores during COVID-19 Catherine Paradis, Senior Research and Policy Analyst, CCSA As the COVID-19 pandemic deepens in Canada, governments have ordered the mandatory closure of all non-essential services (...) to healthcare professionals who perform brief interventions, as well as groups and organizations, and social and health services that can help address domestic violence and support victims. Open versus Closed: The risks associated with liquor retail stores during COVID-19 Canadian Centre on Substance Use and Addiction • Centre canadien sur les dépendances et l’usage de substances Page 2 Potential Risks of Keeping Retail Liquor Stores Open Drinking More Often and in Greater Quantities than Usual In the face

2021 Canadian Centre on Substance Abuse

195. Protective measures for groups vulnerable to COVID-19

of the organisation’s advice, and/or the working constraints of the HTA team. The websites listed below will be reviewed to identify new or updated public health guidance on COVID-19. Additional countries’ and relevant websites used to search for specific reviews are listed in the relevant subsections. ? World Health Organization (WHO) https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical- guidance-publications?healthtopics=b6bd35a3-cf4f-4851-8e80- 85cb0068335b&publishingoffices=aeebab07-3d0c (...) ://www.publichealth.hscni.net/covid-19-coronavirus/guidance- professionals-and-organisations https://www.publichealth.hscni.net/covid-19-coronavirus/guidance-hsc-staff- healthcare-workers-and-care-providers/guidance-healthcare ? Australian Government Department of Health https://www.health.gov.au/resources ? Government of Canada https://www.canada.ca/en/public-health/services/diseases/2019-novel- coronavirus-infection/guidance-documents.html https://www.canada.ca/en/public-health/services/diseases/2019-novel- coronavirus

2021 Health Information and Quality Authority

196. COVID-19 in children and the role of school settings in transmission - first update

COVID-19 in children and the role of school settings in transmission - first update COVID-19 in children and the role of school settings in COVID-19 transmission Global Navigation Other sites: European Centre for Disease Prevention and Control An agency of the European Union Main Navigation Secondary Navigation Search Search Search Search COVID-19 in children and the role of school settings in COVID-19 transmission COVID-19 in children and the role of school settings in COVID-19 transmission (...) Technical report 6 Aug 2020 Cite: COVID-19 in children and the role of school settings in COVID-19 transmission, 6 August 2020. Stockholm: ECDC; 2020. The aim of this document is to provide an overview of the epidemiology and disease characteristics of COVID-19 in children (0-18 years) in EU/EEA countries and the United Kingdom (UK), and an assessment of the role of childcare (preschools; ages 0-<5 years) and educational (primary and secondary schools; ages 5-18 years) settings in COVID-19 transmission

2021 European Centre for Disease Prevention and Control - Covid-19 Guidance

197. Impacts of the COVID-19 Pandemic on Substance Use Treatment Capacity in Canada

Impacts of the COVID-19 Pandemic on Substance Use Treatment Capacity in Canada www.ccsa.ca • www.ccdus.ca Canadian Centre on Substance Use and Addiction • Centre canadien sur les dépendances et l’usage de substances Page 1 Impacts of the COVID-19 Pandemic on Substance Use Treatment Capacity in Canada Key Findings • There was a substantial decrease in the availability and capacity of substance use treatment and harm reduction services in the early phase of the pandemic (March–June) due (...) of virtual care is not equitably distributed, and it cannot completely replace the need for in-person treatment options. Background The response to the COVID-19 pandemic has included many public health measures to contain the spread of the SARS-CoV-2 virus. These measures have substantially affected the provision of and access to services and supports for people who use substances. Some public health measures for COVID-19 have impacted patterns of substance use, the illicit drug supply

2021 Canadian Centre on Substance Abuse

198. Impacts of the COVID-19 Pandemic on People Who Use Substances: What We Heard

Impacts of the COVID-19 Pandemic on People Who Use Substances: What We Heard www.ccsa.ca • www.ccdus.ca Canadian Centre on Substance Use and Addiction • Centre canadien sur les dépendances et l’usage de substances Page 1 Impacts of the COVID-19 Pandemic on People Who Use Substances: What We Heard Approach Data for this report were generated from a qualitative design where 17 key informants were consulted using a convenience sample. The sample included 12 members of the Lived and Living (...) * report a loss of social connection and supports, as well as an increase in isolation, fear and anxiety as a result of the COVID-19 pandemic. Compared to the general population, they are more vulnerable to the health impacts of COVID-19 and the hardships of physical distancing. • Respondents report a higher level of concern associated with the drug supply, its quality, degree of contamination, potency and cost, and their ability to access it given physical distancing recommendations. Risks

2021 Canadian Centre on Substance Abuse

199. Boredom and Stress Drives Increased Alcohol Consumption during COVID-19

Boredom and Stress Drives Increased Alcohol Consumption during COVID-19 Boredom and Stress Drives Increased Alcohol Consumption during COVID-19: NANOS Poll Summary Report CCSA May Omnibus Research | Summary Conducted by Nanos for the Canadian Centre on Substance Use and Addiction, May 2020 Submission 2020-1645 INSERT ISTOCK IMAGE HERE – DELETE THIS BOX ADD ALT-TEXT TO IMAGE AND REMOVE FROM CLIENT LOGO© NANOS RESEARCH SUMMARY Although many Canadians report the same alcohol consumption, one (...) drinking once started. COVID-19 and staying at home • Nearly nine in ten Canadians report staying at home more due to COVID-19 – Eighty-nine per cent of Canadians report staying at home more due to COVID-19 (94% in March), while 10 per cent say that they are staying at home the same amount, and one per cent say less. Canadians who are staying at home more, most frequently say they have been doing so for 10 weeks (34%), followed by 11 weeks (16%), eight weeks (14%) and 12 weeks (13%). Change in alcohol

2021 Canadian Centre on Substance Abuse

200. Vaccinating Pregnant and Lactating Patients Against COVID-19 Full Text available with Trip Pro

Vaccinating Pregnant and Lactating Patients Against COVID-19 Vaccinating Pregnant and Lactating Patients Against COVID-19 | ACOG Clinical Guidance Journals & Publications Patient Education Topics Featured Clinical Topics Hi, Featured Clinical Topics Vaccinating Pregnant and Lactating Patients Against COVID-19 Practice Advisory December 2020 Jump to Resources Share By reading this page you agree to ACOG's Terms and Conditions. ) and the use of the Moderna-1273 COVID-19 vaccine in persons aged (...) ≥ 18 years ( ). ACOG recommends that COVID-19 vaccines should not be withheld from pregnant individuals who meet criteria for vaccination based on ACIP-recommended priority groups. COVID-19 vaccines should be offered to lactating individuals similar to non-lactating individuals when they meet criteria for receipt of the vaccine based on prioritization groups outlined by the ACIP. Individuals considering a COVID-19 vaccine should have access to available information about the safety and efficacy

2021 American College of Obstetricians and Gynecologists